← All UbiTiter issuesUbiTiter Issue #18
ADC Pharmacology, Multispecific Assembly, and Nanobody Discovery
This issue follows how antibody designs become interpretable experiments: tracing payload delivery, linking exposure to response, assembling compatible binders and preserving the evidence behind a sequence.
- antibody-drug conjugates
- quantitative systems pharmacology
- TROP2
- BCMA
- multispecific antibodies
- nanobody discovery
- sequence deposition
The field
This Week in Biologics
Paper 1 · bioRxiv preprint
Quantitative Systems Pharmacology Model for Trop-2 Targeting Antibody-Drug Conjugate in Triple-Negative Breast Cancer
A TROP2 ADC model separates receptor-mediated delivery from circulating SN-38 exposure and explains why response associations need a pharmacological interpretation.
Core finding
Sacituzumab govitecan can deliver SN-38 through TROP2 binding or release it into circulation before tumor entry. Dogru et al. modeled these routes in triple-negative breast cancer and predicted a 33.2% response rate against a 34.0% trial comparator. Removing plasma-to-tumor transport of free SN-38 reduced intracellular exposure to 2.4% and 0.4% of the full-model values in antigen-high and antigen-low cells, respectively.
What's novel
The study uses a mechanistic intervention within the model to estimate the contribution of systemic payload release. It connects that delivery analysis to heterogeneous tumor response, allowing the source of intracellular exposure and the association with TROP2 expression to be examined separately.
Limitations
The two modeled cell populations differ in both TROP2 expression and SN-38 sensitivity, so their response difference cannot isolate the contribution of receptor-mediated delivery. The exposure fractions also depend on the assumed linker-release and transport kinetics; an aggregate response match does not uniquely establish those mechanisms.
In context
The paper shows why an ADC biomarker association needs a pharmacological explanation. For this labile-linker model, better response in antigen-high tumors coexists with a dominant contribution from circulating free payload, because target expression also tracks the assumed susceptibility of the tumor cells.
Paper 2 · CPT: Pharmacometrics & Systems Pharmacology
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma
A joint PKPD model connects belantamab mafodotin exposure, soluble BCMA and M-protein dynamics, distinguishing target binding from disease-marker associations.
Core finding
Clements et al. jointly modeled belantamab mafodotin, soluble BCMA and serum M-protein using 15,860 observations from 510 patients in four DREAMM studies. Free ADC drove M-protein reduction, and M-protein scaled soluble-BCMA production. Higher baseline soluble BCMA was associated with both higher clearance and a stronger modeled drug effect on M-protein.
What's novel
The analysis combines drug exposure, target binding and disease-marker dynamics in one fit. Sensitivity analysis guided the removal of redundant mechanisms, producing a model in which changes in target abundance can alter the free fraction while disease response feeds back into target production.
Limitations
Equal elimination rates for free and bound ADC make total-drug clearance constant over time within a patient, so the baseline soluble-BCMA association is not evidence of binding-driven elimination. Cycle-start M-protein sampling also leaves the simulated behavior between doses dependent on model structure, which matters when comparing dosing intervals.
In context
The work separates soluble target as a binding partner from soluble target as a marker of disease. That distinction explains how higher baseline BCMA can be associated with both less favorable exposure and a larger modeled response per unit of free drug, without treating either covariate relationship as an isolated causal mechanism.
Paper 3 · Protein Science
Strategy for modular assembly of tetravalent, multispecific antibodies
A fixed light chain supports modular tetravalent assembly, while binding, signaling and uptake measurements reveal the contribution of molecular geometry.
Core finding
Mallette et al. selected PD-L1 and CD30 binders from a library with a fixed trastuzumab light chain, then combined them into four tetravalent molecules containing two CD30 arms and two distinct PD-L1 arms. The constructs retained checkpoint-blocking activity and strong cellular uptake despite weaker apparent PD-L1 affinity than the parental IgGs. Four Fab–antigen structures showed how the shared light chain supported the different binding interfaces.
What's novel
The strategy makes light-chain compatibility a property of binder discovery rather than a pairing problem to solve after combining independently selected antibodies. The structural work connects that selection strategy to the modular assembly: the same light chain makes different antigen contacts while supporting diverse heavy-chain loops.
Limitations
Comparable reporter activity does not negate the change in BLI affinity, because binding kinetics and downstream signaling are different endpoints. Steric effects and CD30/PD-L1 co-engagement are proposed explanations for the discrepancy, but the experiments do not isolate their contributions.
In context
This format illustrates how a common light chain can simplify multispecific assembly without making the individual paratopes independent of their surroundings. The assembled geometry remains part of the pharmacology, so binding, signaling and uptake provide complementary evidence about the resulting molecule.
Paper 4 · Xaira company blog; company-reported results
De Novo Design of Progressable Antibodies to Therapeutic Targets
Xaira reports two routes from computational design to binders; different screening stages make the reported hit fractions unsuitable for direct comparison.
Core finding
Xaira reports 18 XA-1 binders from 182 designs and seven XA-4 cell binders from 92 candidates selected after panning 60,000 designs.
What's novel
The report describes two distinct routes from computational design to experimental binders.
Limitations
The fractions use different selection-stage denominators, preventing a direct comparison of design success.
In context
The screening workflow is part of the result: enrichment changes which candidates reach the final assay.
Paper 5 · mAbs, Letter to the Editor
NanoSaurus: addressing the urgent need for open access in single-domain antibody research
NanoSaurus links complete nanobody sequences with accession numbers, contributor identities and validation records to support traceability and reuse.
Core finding
Di Filippo et al. describe NanoSaurus as a database connecting complete nanobody sequences with accession numbers, contributor identities and available validation evidence. Entries also record applications, publications and binder origin, and can be updated as further information becomes available. The authors propose routine sequence deposition as a journal requirement.
What's novel
The resource combines molecular identity with attribution and an evolving evidence record. Its accession-number and ORCID requirements provide a common reference for linking subsequent experiments to the original sequence and contributors.
Limitations
Traceability and functional validation remain distinct: an accession identifies the sequence, while the linked assays determine which biological claims are supported. Record membership alone therefore cannot establish equivalent validation across binders.
In context
The letter frames sequence deposition as part of making antibody research reproducible. Its contribution is a shared record that can connect a named binder to the molecule actually tested, while preserving credit as that molecule is reused.
Primary sources
- [1] Quantitative Systems Pharmacology Model for Trop-2 Targeting Antibody-Drug Conjugate in Triple-Negative Breast Cancer (bioRxiv preprint)
- [2] Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma (CPT: Pharmacometrics & Systems Pharmacology)
- [3] Strategy for modular assembly of tetravalent, multispecific antibodies (Protein Science)
- [4] De Novo Design of Progressable Antibodies to Therapeutic Targets (Xaira company blog; company-reported results)
- [5] NanoSaurus: addressing the urgent need for open access in single-domain antibody research (mAbs, Letter to the Editor)